These data suggested that gy1 can specifically target PSMA positive tumor in vivo, which encourage the development of PSMA targeted imaging and therapy using gy1, such as intraoperative optical imaging, PET imaging, nanomedicine and antibody drug conjugate. The gene discussed is FOLH1; the disease is neoplasm.